Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

  • Ikuo Nakamura,
  • Kais Zakharia,
  • Bubu A. Banini,
  • Dalia S. Mikhail,
  • Tae Hyo Kim,
  • Ju Dong Yang,
  • Catherine D. Moser,
  • Hassan M. Shaleh,
  • Sarah R. Thornburgh,
  • Ian Walters,
  • Lewis R. Roberts
  • Article
  • Metrics
  • Comments
  • Media Coverage

The following information is missing from the Funding section: This research was supported by a National Institutes of Health (NIH) grant, 3R01CA165076-03S2, Research Supplement to Promote Diversity in Health-Related Research, to Hassan M. Shaleh.

Reference

  1. 1. Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, et al. (2014) Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS ONE 9(4): e92273. pmid:24710173

Citation: Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, et al. (2015) Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS ONE 10(11): e0142355. https://doi.org/10.1371/journal.pone.0142355

Published: November 3, 2015

Copyright: © 2015 Nakamura et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited